Botanicals Characterization In Clinical Trials Of Concern, JAMA Says
This article was originally published in The Tan Sheet
Executive Summary
Providing adequate descriptions of botanicals studied in published clinical trials is an area of concern for the Journal of the American Medical Association, the group said.
You may also be interested in...
St. John's Wort Prior Study Limitations Stressed In JAMA Research
Previous studies of St. John's wort have had numerous flaws - such as small sample sizes and low doses - a recent study led by Richard Shelton, MD, Vanderbilt University, et al., states.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands